Merck & Co. (MRK) 10-K Red Flags
Risk signals extracted deterministically from Merck & Co.’s SEC 10-K/10-Q XBRL filings — no LLM, every finding cites the underlying data.
Detected red flags (16)
- Receivables outpacing revenue: Accounts receivable grew +14.6% YoY vs revenue growth of +1.3%. The +13.3% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
- Free cash flow deteriorating: FCF declined +31.7% YoY (from $18.10B to $12.36B). With OCF at $16.47B and capex at $4.11B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
- Interest coverage deteriorating below 3x: Interest coverage fell from 15.09x to 0.32x. Operating income of $365.0M covers interest of $1.15B only 0.32x — approaching the threshold where debt service becomes constrained. Monitor for covenant breaches.
- Restatement of financial statements: The term "restatement of" "previously issued" appears in 5 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
- R&D intensity declining: R&D as % of revenue fell from 28.0% to 24.3%. This may signal reduced innovation investment — potentially impacting long-term competitive position. Compare with peer R&D trends.
- NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: Revenue grew +1.3% but receivables grew +14.6% — the receivables-to-revenue gap suggests growth may be partially driven by extended credit terms rather than genuine demand. If DSO continues to rise, a revenue reversal or bad-debt charge could follow.
- Endogenous analysis: Free cash flow declined despite stable or rising capex, indicating the cash burn is operational rather than investment-driven. This is a structural concern — cost reduction or asset sales may be needed to restore FCF.
- 2 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Impairment charge, Off-balance sheet arrangements.
- Ongoing high-severity risk language: Restatement of financial statements.
- Market cap $333.31B at $135.10 per share.
- Trailing P/E 18.56, P/S 5.13, P/B 7.95.
- Receivables outpacing revenue: Accounts receivable grew +14.6% YoY vs revenue growth of +1.3%. The +13.3% spread suggests extended credit terms, channel stuffing risk, or collection deterioration. Investigate the allowance for doubtful accounts and DSO trend.
- Free cash flow deteriorating: FCF declined +31.7% YoY (from $18.10B to $12.36B). With OCF at $16.47B and capex at $4.11B, cash generation capacity is weakening — monitor for dividend/buyback sustainability.
Filings & ownership
- Latest annual report (10-K) filed Feb 24, 2026.
- Latest quarterly report (10-Q) filed Aug 7, 2026.
- 5 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 16 sell transactions — net selling $28.0M.
- ~10,000+ recent 13F-HR filings reference Merck & Co.; broad institutional reporting.
- Recent filers include LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 16 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 4 recent 13G passive institutional ownership notices.
Full MRK analyst report
Valuation (DCF & Graham), technicals, macro exposure, risk scorecard and 13F/13D ownership.
View full report →Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.